Low Prevalence of Antibodies against Human Immunodeficiency Virus in Finnish Haemophiliacs

Rasi, Vesa; Ikkala, Esko; Myllylä, G.; Nevanlinna, H. R.

doi:10.1111/j.1423-0410.1991.tb00893.x

Cited by 12 publications

(10 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Incomplete ascertainment of cases, non‐representative samples, and survey non‐response may result in under‐reporting of the number of people with haemophilia A in all of the studies (Tables 1 and 5). An incomplete ascertainment of cases, especially mild cases, occurs when countries count only patients that use their HTCs or other care sources [2,14,29–35,41–52,55,57,58,76,78,79]. For example, the WFH data for the United States is based solely on patients who use federally supported haemophilia treatment centres for care which accounted for about 70% of all patients identified in a more complete sample [9].…”

Section: Resultsmentioning

confidence: 99%

A study of variations in the reported haemophilia A prevalence around the world

et al. 2009

View full text Add to dashboard Cite

The objectives of this paper were to study the reported haemophilia A prevalence (per 100 000 males) on a country-by-country basis and address the following: Does the reported prevalence of haemophilia A vary by national economies? We collected prevalence data for 106 countries from the World Federation of Hemophilia (WFH) annual global surveys and the literature. We found that the reported haemophilia A prevalence varied considerably among countries, even among the wealthiest of countries. The prevalence (per 100 000 males) for high income countries was 12.8 +/- 6.0 (mean +/- SD) whereas it was 6.6 +/- 4.8 for the rest of the world. Within a country, there was a strong trend of increasing prevalence over time--the prevalence for Canada ranged from 10.2 in 1989 to 14.2 in 2008 (R = 0.94 and P < 0.001) and for the United Kingdom it ranged from 9.3 in 1974 to 21.6 in 2006 (R = 0.94 and P < 0.001). Prevalence data reported from the WFH compared well with prevalence data from the literature. Patient registries generally provided the highest quality of prevalence data. The lack of accurate country-specific prevalence data has constrained planning efforts for the treatment and care of people with haemophilia A. With improved information, healthcare agencies can assess budgetary needs to develop better diagnostic and treatment facilities for affected patients and families and work to ensure adequate supplies of factor VIII concentrates for treatment. In addition, this information can help manufacturers plan the production of concentrates and prevent future shortages.

show abstract

Section: Resultsmentioning

confidence: 99%

A study of variations in the reported haemophilia A prevalence around the world

et al. 2009

View full text Add to dashboard Cite

show abstract

“…In contrast to both Ireland and the UK, Finland chose to remain self-sufficient in blood and, despite the clamour to embrace concentrates internationally, persisted with the use of cryoprecipitate, a decision that had significant benefits for its haemophilia community: only two out of 213 haemophiliacs contracted HIV (0.94%) (Ebeling et al 1990, Rasi et al 1991. It was a figure remarkably similar to that of those haemophiliacs in the UK that had remained on cryoprecipitate.…”

Section: Risk Science and Blood: The Uk And Finland In Comparative Pmentioning

confidence: 69%

Risk, science and blood: The politics of the haemophilia crisis in Ireland

Taylor

Power

2010

Health, Risk & Society

View full text Add to dashboard Cite

“…In conclusion, the current products used for treating bleeding diseases in Finland are very safe in terms of the risk of virus transmission [1–3]. Not a single seroconversion for either HBV, HCV or HIV has been detected among sole users of S/D‐treated factor products.…”

Section: Discussionmentioning

confidence: 99%

“…Finnish haemophilia patients have been treated almost exclusively with domestic products derived from plasma of voluntary, non‐remunerated donors. Only two Finnish haemophiliacs have previously been found to be HIV‐infected [3].…”

mentioning

confidence: 99%

Viral markers and use of factor products among Finnish patients with bleeding disorders

Ebeling¹,

Rasi²,

Laitinen³

et al. 2001

Haemophilia

Self Cite

View full text Add to dashboard Cite

In the seventh national voluntary cross‐sectional survey (in 1999) of Finnish patients with haemophilia A or B, type 3 von Willebrand disease or factor XIII deficiency, a plasma sample was received from 193 patients (67%). The samples were tested for hepatitis B and C, human immunodeficiency virus (HIV) and human T‐cell leukaemia virus (HTLV) antibodies. Fifty‐one percent of the patients were hepatitis C antibody positive and 34% hepatitis B core antibody positive. None of the patients had antibodies against HIV or HTLV. Eighteen percent of the patients had an elevated alanine aminotransferase activity. Abnormal alanine aminotransferase was significantly associated with hepatitis C seropositivity. No new seroconversions were detected among the haemophiliacs or patients with type 3 von Willebrand disease when compared with the last two surveys in 1993 and 1996, and there was no seroconversion in sole users of solvent/detergent‐treated factor products. Currently, 32% of the patients use prophylactic factor treatment as their principal mode of therapy, particularly the younger patients with severe forms of the bleeding diseases.

show abstract

Low Prevalence of Antibodies against Human Immunodeficiency Virus in Finnish Haemophiliacs

Cited by 12 publications

References 8 publications

A study of variations in the reported haemophilia A prevalence around the world

A study of variations in the reported haemophilia A prevalence around the world

Risk, science and blood: The politics of the haemophilia crisis in Ireland

Viral markers and use of factor products among Finnish patients with bleeding disorders

Contact Info

Product

Resources

About